The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphataseShow others and affiliations
2022 (English)In: Nucleic Acids Research, ISSN 0305-1048, E-ISSN 1362-4962, Vol. 50, no 6, p. 3505-3522
Article in journal (Refereed) Published
Abstract [en]
Despite MYC dysregulation in most human cancers, strategies to target this potent oncogenic driver remain an urgent unmet need. Recent evidence shows the PP1 phosphatase and its regulatory subunit PNUTS control MYC phosphorylation, chromatin occupancy, and stability, however the molecular basis remains unclear. Here we demonstrate that MYC interacts directly with PNUTS through the MYC homology Box 0 (MB0), a highly conserved region recently shown to be important for MYC oncogenic activity. By NMR we identified a distinct peptide motif within MB0 that interacts with PNUTS residues 1-148, a functional unit, here termed PNUTS amino-terminal domain (PAD). Using NMR spectroscopy we determined the solution structure of PAD, and characterised its MYC-binding patch. Point mutations of residues at the MYC-PNUTS interface significantly weaken their interaction both in vitro and in vivo, leading to elevated MYC phosphorylation. These data demonstrate that the MB0 region of MYC directly interacts with the PAD of PNUTS, which provides new insight into the control mechanisms of MYC as a regulator of gene transcription and a pervasive cancer driver.
Place, publisher, year, edition, pages
Oxford, United Kingdom: Oxford University Press, 2022. Vol. 50, no 6, p. 3505-3522
National Category
Biochemistry Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-183749DOI: 10.1093/nar/gkac138ISI: 000764239500001PubMedID: 35244724OAI: oai:DiVA.org:liu-183749DiVA, id: diva2:1646791
Note
Funding: Canadian Institutes of Health Research [FRN156167 to L.Z.P., FDN154328 to C.H.A., FDN143312 to D.W.A.]; Swedish Cancer Society [20 1276 PjF 01 H to M.S.]; Swedish Childhood Cancer Fund [PR2019-0143 project grant to M.S., TJ2018-0103 postdoc award to A.A.]; Swedish Research Council [2018-04390 to M.S., 2016-05369 to B.W.]; Princess Margaret Cancer Centre; Princess Margaret Cancer Foundation; Ontario Ministry of Health; the Structural Genomics Consortium is a registered charity [1097737] that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196]; EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510]; Janssen, Merck KGaA (aka EMD in Canada and US); Pfizer; Takeda; NMR access at the ProLinC core facility was funded by Linköping University; the computations were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at the National Supercomputer Centre (NSC) in Linköping; L.Z.P. and D.W.A. hold Tier 1 Canada Research Chairs in Molecular Oncology and Membrane Biogenesis, respectively. Funding for open access charge: Canadian Institutes of Health Research.
2022-03-242022-03-242025-02-20Bibliographically approved
In thesis